SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fabrizio Cantini, Carlotta Nannini, Laura Niccoli, Florenzo Iannone, Giovanni Delogu, Giacomo Garlaschi, Alessandro Sanduzzi, Andrea Matucci, Francesca Prignano, Michele Conversano, Delia Goletti, Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice, Autoimmunity Reviews, 2015, 14, 6, 503

    CrossRef

  2. 2
    Song Liu, Jianan Ren, Jieshou Li, IL-17RA in Intestinal Inflammation, Inflammatory Bowel Diseases, 2015, 21, 1, 154

    CrossRef

  3. 3
    Maeve McLaughlin, Andrew Östör’s, Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, Expert Opinion on Drug Safety, 2015, 14, 3, 429

    CrossRef

  4. 4
    Atsushi Ogata, Takayoshi Morita, Yuji Yoshida, Toshio Tanaka, Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis, Therapeutic Delivery, 2015, 6, 3, 283

    CrossRef

  5. 5
    Soken-Nakazawa J Song, Kazuyuki Yoshizaki, Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy, Expert Opinion on Drug Metabolism & Toxicology, 2015, 11, 2, 307

    CrossRef

  6. 6
    Yuji Yoshida, Toshio Tanaka, Interleukin 6 and Rheumatoid Arthritis, BioMed Research International, 2014, 2014, 1

    CrossRef

  7. 7
    Andra F. Negoescu, Andrew J. K. Östör, Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab, Rheumatology and Therapy, 2014,

    CrossRef